Search Within

Population Sciences Research Program

  1. "Hematologic Malignancies Research"
Formats
  1. Meeting Abstract (87)
  2. Journal Article (49)
  3. Research Letter (4)
  4. Book Section (1)
  5. Correspondence (1)
Groups
  1. Center for Hematologic Malignancies (142)
  2. Hematologic Malignancies Research (142)
  3. Department of Medicine (140)
  4. Hematologic Malignancies, Division of (130)
  5. Epidemiology and Biostatistics (106)
  6. Sloan Kettering Institute Postdocs (97)

More Groups

People
  1. Alexander Lesokhin (65)
  2. Andriy Derkach (63)
  3. Malin Hultcrantz (58)
  4. Urvi Shah (58)
  5. Sham Mailankody (55)
  6. Hani Hassoun (53)

More People

Years
  1. 2024 (3)
  2. 2023 (35)
  3. 2022 (23)
  4. 2021 (13)
  5. 2020 (13)
  6. 2019 (7)

More Years

Publications
  1. Blood (53)
  2. Clinical Lymphoma, Myeloma and Leukemia (15)
  3. Journal of Clinical Oncology (13)
  4. Blood Advances (5)
  5. Clinical Cancer Research (4)
  6. Blood Cancer Journal (3)

More Publications

Publishers
  1. American Society of Hematology (58)
  2. Elsevier Inc. (18)
  3. American Society of Clinical Oncology (13)
  4. Nature Publishing Group (11)
  5. American Association for Cancer Research (9)
  6. Wiley Blackwell (4)

More Publishers

Results (142)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 trial of colesevelam for lenalidomide-associated diarrhea
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Korde, N.; Mailankody, S.; Shekarkhand, T.; Burge, M.; Maclachlan, K. H.; Patel, D.; Shah, U. A.; Chung, D. J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Maintenance Therapy Cessation for Sustained MRD Negative Multiple Myeloma Patients
    Meeting Abstract

    Korde, N.; Diamond, B.; Burge, M.; Hassoun, H.; Landau, H.; Hultcrantz, M.; Mailankody, S.; Maclachlan, K. H.; Shah, U. A.; Derkach, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Carfilzomib, lenalidomide and dexamethasone (KRd) vs bortezomib, lenalidomide, and dexamethasone (VRd) as induction therapy in newly diagnosed high-risk multiple myeloma
    Meeting Abstract

    Tan, C.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Patel, D.; Maclachlan, K. H.; Lahoud, O. B.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy
    Correspondence

    Nath, K.; Shekarkhand, T.; Salcedo, M.; Derkach, A.; Rueda, S.; Chansakul, A.; Hulcrantz, M.; Korde, N.; Shah, U. A.; Tan, C.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Sustained minimal residual disease negativity in multiple myeloma is associated with stool butyrate and healthier plant-based diets
    Journal Article

    Shah, U. A.; Maclachlan, K. H.; Derkach, A.; Salcedo, M.; Barnett, K.; Caple, J.; Blaslov, J.; Tran, L.; Ciardiello, A.; Burge, M.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Clinical efficacy of daratumumab (DARA)-based second line therapy after DARAcontaining and DARA-free induction therapies in multiple myeloma: A single center experience
    Meeting Abstract

    Ciardiello, A.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Lu, S. X.; Patel, D.; Maclachlan, K.; Lahoud, O. B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • African American patients with smoldering multiple myeloma may have a lower risk of progression compared to White patients
    Meeting Abstract

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A. M.; Hassoun, H.; Lu, S. X.; Patel, D.; Shah, U. A.; Tan, C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Evaluating serum-free light chain ratio as a biomarker for multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A. M.; Hassoun, H.; Lu, S. X.; Patel, D.; Shah, U. A.; Tan, C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Nutrition perceptions, needs and practices among patients with plasma cell disorders
    Research Letter

    Malik, M. A.; Sweeney, N. W.; Jafri, M.; Derkach, A.; Chmielewski, C.; Adintori, P. A.; Mailankody, S.; Korde, N.; Tan, C. R.; Hassoun, H.; more...
    Blood Cancer Journal (2022)

    Fulltext@MSK | Save
  • Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis
    Journal Article

    Piedra, K.; Peterson, T.; Tan, C.; Orozco, J.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Lesokhin, A.; Shah, U.; Lu, S.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save